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Transgender care is a topic that has received greater social awareness and attention in 
popular culture in recent years. Awareness of transgender health care needs within the 
pediatric population has similarly increased as many centers experience a rapid rise in 
referrals. In the Netherlands, the Dutch Gender Identity Clinic saw progressively increasing 
numbers of pediatric and adolescent referrals through the early 2000s, with a gradual 
decrease in the mean age of adolescent referrals. Children’s Hospital Boston saw a rapid 
quadrupling of cases soon after establishing their Gender Management Service in 2007. Our 
own endocrinology department has seen a dramatic increase in referrals since 2013, even 
without an established multidisciplinary clinic. This is thought to be a result of greater social 
acceptance and increasing exposure in the media, making it less threatening for a 
transgender individual to come out, rather than to an increasing prevalence of the condition. 
Prevalence estimates vary widely depending on how transgender is defined, the population 
surveyed, and how the data were collected. Although it was thought to be rare within the 
general population, 1 in 7000–20,000 natal males and 1 in 33,000–50,000 natal females, 
these numbers are likely underestimates due to the persistent social stigma. In fact, the 
prevalence of transgender identity may be as high as 355 per 100,000, or about 0.35% of the 
general population based on a recent meta-analysis by Collin, et al. [J Sex Med, 13(4):613, 
2016].
Two sets of guidelines are commonly used for the endocrine transition of transgender adults 
and adolescents: the 2009 Endocrine Society Clinical Practice Guidelines (currently 
undergoing revision) and the World Professional Association for Transgender Health 
(WPATH) Standards of Care, Version 7. The two guidelines largely match with regards to 
the medical transition of transgender adolescents and recommend the use of GnRH analogs 
soon after the onset of endogenous puberty, followed by administration of gender affirming 
hormones (testosterone for transgender males and estradiol for transgender females), after 
age 16. Although it remains controversial, many practitioners recommend liberalizing the 
age at initiation of gender affirming hormone treatment in selected cases, and the upcoming 
revision of the Endocrine Society guidelines, expected by the end of 2016, will likely allow 
for increased flexibility in timing.
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Despite this, a recent survey at the 2015 annual meeting of the American Association of 
Clinical Endocrinologists showed that even among endocrinologists, 74% assessed 
themselves as “not at all” or “a little” competent in transgender care. Therefore, awareness 
has not necessarily been paralleled by resources, medical knowledge, or proficiency, and 
numerous gaps persist in delivering optimal healthcare in this population.
Many studies document the high incidence of psychological comorbidities experienced by 
transgender youth. These include high rates of bullying and harassment, frequent 
victimization by violence, increased rates of substance abuse and misuse of prescription 
drugs, high-risk sexual behaviors resulting in increased incidences of sexually transmitted 
infections including HIV, and most concerningly, a high prevalence of self-harm and 
suicidality. Evidence suggests that many of these comorbidities are exacerbated by family 
and peer rejection, and there appears to be a link between bullying and substance abuse. As 
mentioned earlier, health care providers often have received little education or training in the 
care of transgender individuals. Although efforts in this regard are increasing, young 
transgender adults are frequently reluctant to engage the healthcare system, in part because 
of concerns for bias and discrimination and the often-correct perception that primary care 
providers have inadequate knowledge of transgender healthcare. In particular there is a 
deficiency of mental health providers with sufficient expertise to care for transgender 
adolescents. Furthermore, it is not always easy to locate those providers who do have such 
expertise. Both the Endocrine Society and WPATH guidelines emphasize the critical nature 
of careful psychological evaluations and provision of continuing mental health services to 
this population.
Additionally, there are many financial barriers to care in the adolescent transgender 
population. For example, GnRH analogs are prohibitively expensive without insurance 
authorization, typically costing $15,000–20,000 per year for depot preparations of leuprolide 
acetate or a histrelin subdermal implant. Insurance companies often deny coverage of these 
medications for transgender teens. Although a lower cost option exists (a histrelin implant 
marketed for use in men with prostate cancer), coverage for this also is frequently denied by 
insurance carriers. Less expensive options for suppression of endogenous sex hormone 
effects include spironolactone for transgender males and depot medroxyprogesterone acetate 
for transgender females. However, these alternatives are less effective than GnRH analogs 
and may have additional adverse effects, i.e., electrolyte abnormalities and weight gain.
Recently, the US Department of Health and Human Services released the “final rule” 
clarifying the application of Section 1557 of the Affordable Care Act, which provides 
protection against healthcare discrimination on the basis of sex, race, age, and other 
characteristics. This rule appears to prohibit denial of transgender care by HHS-funded 
entities and insurance plans offered in the Health Insurance Marketplace. As the effects of 
this rule percolate through the healthcare system and the courts, there is hope that the 
financial coverage of transgender healthcare will improve.
Research is an additional area that is insufficient in the transgender patient population. 
Despite the growing numbers of transgender patients presenting to our clinics, the spectrum 
of gender dysphoria is broad and subsequent treatment decisions can vary widely, making 
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well-powered studies difficult to conduct. Therefore, existing recommendations for 
laboratory and clinical monitoring during puberty suppression or gender affirming hormone 
therapy are extensive and largely address theoretical risks of treatment rather than clinical 
evidence of adverse events in this population. Currently, practitioners for the most part rely 
on expert opinion and insight drawn from analogous physiological conditions to guide 
ongoing treatment decisions.
In addition, transgender care is itself still a new and emerging field, and shifts in definition 
and understanding impact clinical care. An accurate grasp of patient outcomes is essential 
for providing treatment recommendations and anticipatory guidance. Unfortunately, much of 
our current understanding of therapeutic needs, monitoring, and outcomes is built upon 
research performed when gender dysphoria/gender identity disorder was more broadly 
defined than the current designation and treatment methods were more variable. For 
example, previous studies reported that the great majority of prepubertal children with 
gender dysphoria “desisted” by the time they reached the early stages of puberty. It is 
postulated, however, that true rates of desistance are lower and persistence higher within 
today’s “gender dysphoria” population compared to the earlier studies that had broader 
inclusion criteria. Research confirming these suspicions has not actually been repeated.
Likewise, some studies have suggested that poor mental health outcomes in transgender 
youth can persist even after treatment. However, gradual refinement of accepted practice 
makes the treatment standards in these studies outdated. In addition, such studies often were 
not conducted with truly comparable control groups, limiting our ability to draw confident 
conclusions. The group in the Netherlands has followed a treatment cohort of 55 adolescents 
and has found promising psychological outcomes in the early post-treatment period. 
Nevertheless, long-term medical and mental health outcomes after care according to the 
current standard are largely unknown, and will remain unknown for years.
Transgender youth today live in an environment that is far more open and accepting than it 
was just a few years ago, but there remain many difficulties for them to overcome. 
Furthermore, in light of the above issues, transgender healthcare still has a long way to go. 
Additional funding for research into mental health outcomes; effectiveness of treatment 
modalities; and social, economic, and healthcare disparities is clearly needed. Additional 
education of the public and government representatives is also needed to further decrease 
bias and the stigma attached to being transgender in the U.S. today.
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